SCHEMBL4516902

SCHEMBL4516902

CC(C)(C)OC(=O)N1CCN(c2ccc(S(C)(=O)=O)cn2)CC1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 15/20 0.74
▸ CKS1B P61024 1/20 0.53
▸ SKP1 P63208 1/20 0.53
▸ SKP2 Q13309 1/20 0.53
▸ DDB1 Q16531 1/20 0.52
▸ CRBN Q96SW2 1/20 0.52
▸ MAP4K4 O95819 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ GAA P10253 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513884 0.86 GPR119 (0.60) GPR119
SCHEMBL16430912 0.83 GPR119 (0.55) GPR119ALDH1A1HSD17B10TSHR
SCHEMBL28956351 0.82 DDB1 (0.62) GPR119CKS1BSKP1SKP2DDB1
SCHEMBL30261848 0.82 DDB1 (0.62) GPR119CKS1BSKP1SKP2DDB1
SCHEMBL13279435 0.82 GPR119 (0.60) GPR119CKS1BSKP1SKP2DDB1
SCHEMBL29890806 0.82 GPR119 (0.60) GPR119CKS1BSKP1SKP2DDB1
SCHEMBL1594238 0.82 GPR119 (0.57) GPR119CKS1BSKP1SKP2DDB1
SCHEMBL1432329 0.81 GPR119 (0.56) GPR119CKS1BSKP1SKP2DDB1
SCHEMBL1904170 0.81 ADK (0.59) GPR119CKS1BSKP1SKP2DDB1
SCHEMBL265889 0.81 MAP4K4 (0.60) GPR119CKS1BSKP1SKP2DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203676-A1 G-protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-08-13 — — US disclosed
US-20090203676-A1 G-protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-08-13 — — US disclosed
US-20090203676-A1 G-protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-08-13 — — US disclosed
CN-101252929-A G protein-coupled receptor agonists PROSIDION LTD (GB) 2008-08-27 — — CN disclosed
EP-1909791-A1 G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2008-04-16 — — EP disclosed
WO-2007003964-A1 G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203676-A1 G-protein Coupled Receptor Agonists GPR119, GCGR, GPBAR1 GPR119 1/4885CKS1B 3909/4885SKP1 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback